Community-acquired Pneumonia
Conditions
Keywords
Community-acquired infections, Pneumonia, Clinical Stability, Antibiotics, Combination therapy, Atypical bacteria
Brief summary
The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
Interventions
DRUGBeta lactam (amoxicillin / clav. acid OR cefuroxime)
1.2 g 4x/d OR 1.5 g 3x/d IV
DRUGBeta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)
1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
Sponsors
University Hospital, Geneva
Swiss National Fund for Scientific Research
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>=18 years * New infiltrate on chest X-ray, unexplained by another disease process * Presence of at least two of the following findings suggestive of pneumonia: fever or hypothermia, new or increasing cough, sputum production, pleuritic chest pain, tachypnea, dyspnea or focal signs on chest examination * Need for hospitalization as defined by the emergency physician in charge of the patient
Exclusion criteria
* Allergy to one of the study drugs * Pregnancy * Severe immunosuppression * Recent (\<14 d) hospitalization, or currently hospitalized since \> 48 hours * Residency in a nursing home * Previous use of more than 24 hours of any antibiotic * Severe community-acquired pneumonia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Clinical Stability (hours) | 30 days |
Secondary
| Measure | Time frame |
|---|---|
| All cause mortality | in-hospital, at 30 and at 90 days |
| length of stay | 30 days |
Countries
Switzerland
Outcome results
None listed